Market Overview

Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter

Share:
Related BIIB
Exclusive: Verastem CEO Talks Duvelisib, Pipeline Data, And Further Upside For The Stock
Benzinga's Top Upgrades, Downgrades For July 11, 2017
Biotechs On A Hot Streak, And Could Be 'Cooking With Gas' (Investor's Business Daily)
Related AMGN
Merck Falls As FDA Puts Hold On 3 Keytruda Myeloma Studies
Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days
Biotechs On A Hot Streak, And Could Be 'Cooking With Gas' (Investor's Business Daily)

Below are the top biotechnology stocks on the NASDAQ in terms of earnings estimate for the next quarter.

Biogen Idec (NASDAQ: BIIB) is estimated to post earnings of $2.07 per share in the September quarter. Biogen Idec's trailing-twelve-month revenue is $5.64 billion.

Amgen (NASDAQ: AMGN) is expected to earn $1.80 per share in the September quarter. Amgen's trailing-twelve-month operating margin is 34.08%.

Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ) is likely to earn $1.46 per share in the June quarter. Jazz Pharmaceuticals had $387.20 million in total cash for the latest quarter.

Celgene (NASDAQ: CELG) may earn $1.45 per share in the September quarter. Celgene's PEG ratio is 0.94.

Posted-In: Biotechnology Industry Highest EPS Estimates NASDAQ StocksTrading Ideas

 

Related Articles (AMGN + BIIB)

View Comments and Join the Discussion!